Which companies overlap with Grupo Espanol Multidisciplinario del Cancer Digestivo's portfolio?

Top competitors by shared drug class: Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh, Bristol-Myers Squibb, Centre Oscar Lambret, EMD Serono Research & Development Institute, Inc., GERCOR - Multidisciplinary Oncology Cooperative Group.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/grupo-espanol-multidisciplinario-del-cancer-digestivo.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-18 · How we verify

Grupo Espanol Multidisciplinario del Cancer Digestivo — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Grupo Espanol Multidisciplinario del Cancer Digestivo pipeline: 0 marketed, 0 filed, 2 Phase 3, 8 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 8 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
5-Fluoruracil	5-Fluoruracil	phase 3	Antimetabolite	Thymidylate synthase	Oncology
total neoadjuvant therapy	total neoadjuvant therapy	phase 3

Therapeutic area mix

Oncology · 6

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh · 1 shared drug class
Bristol-Myers Squibb · 1 shared drug class
Centre Oscar Lambret · 1 shared drug class
EMD Serono Research & Development Institute, Inc. · 1 shared drug class
GERCOR - Multidisciplinary Oncology Cooperative Group · 1 shared drug class
Hoffmann-La Roche · 1 shared drug class
Iwate Medical University · 1 shared drug class
Asan Medical Center · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Grupo Espanol Multidisciplinario del Cancer Digestivo:

Cite this brief

Drug Landscape (2026). Grupo Espanol Multidisciplinario del Cancer Digestivo — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/grupo-espanol-multidisciplinario-del-cancer-digestivo. Accessed 2026-05-18.